196 related articles for article (PubMed ID: 7915820)
1. High affinity agonist binding to the dopamine D3 receptor: chimeric receptors delineate a role for intracellular domains.
Robinson SW; Jarvie KR; Caron MG
Mol Pharmacol; 1994 Aug; 46(2):352-6. PubMed ID: 7915820
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a chimeric human dopamine D3/D2 receptor functionally coupled to adenylyl cyclase in Chinese hamster ovary cells.
Van Leeuwen DH; Eisenstein J; O'Malley K; MacKenzie RG
Mol Pharmacol; 1995 Aug; 48(2):344-51. PubMed ID: 7651368
[TBL] [Abstract][Full Text] [Related]
3. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors.
Chio CL; Lajiness ME; Huff RM
Mol Pharmacol; 1994 Jan; 45(1):51-60. PubMed ID: 8302280
[TBL] [Abstract][Full Text] [Related]
4. Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain.
Levant B; Grigoriadis DE; DeSouza EB
J Pharmacol Exp Ther; 1992 Sep; 262(3):929-35. PubMed ID: 1356154
[TBL] [Abstract][Full Text] [Related]
5. [3H]quinpirole binding to putative D2 and D3 dopamine receptors in rat brain and pituitary gland: a quantitative autoradiographic study.
Levant B; Grigoriadis DE; DeSouza EB
J Pharmacol Exp Ther; 1993 Feb; 264(2):991-1001. PubMed ID: 8437136
[TBL] [Abstract][Full Text] [Related]
6. Chimeric dopamine D2/angiotensin AT1 receptors: role of the length of third intracellular loop of D2 receptors in conferring specificity of receptor binding and G-protein coupling.
Chen H; Zhang YY; Han QD
Zhongguo Yao Li Xue Bao; 1997 May; 18(3):209-13. PubMed ID: 10072934
[TBL] [Abstract][Full Text] [Related]
7. Expression and pharmacological characterization of the human D3 dopamine receptor.
Freedman SB; Patel S; Marwood R; Emms F; Seabrook GR; Knowles MR; McAllister G
J Pharmacol Exp Ther; 1994 Jan; 268(1):417-26. PubMed ID: 8301582
[TBL] [Abstract][Full Text] [Related]
8. Differential pharmacological profile of striatal and cerebellar dopamine receptors labeled by [3H]quinpirole: identification of a discrete population of putative D3 receptors.
Levant B; DeSouza EB
Synapse; 1993 May; 14(1):90-5. PubMed ID: 8099762
[TBL] [Abstract][Full Text] [Related]
9. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A
J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
[TBL] [Abstract][Full Text] [Related]
10. Autoradiographic mapping of dopamine-D2/D3 receptor stimulated [35S]GTPgammaS binding in the human brain.
Sóvágó J; Makkai B; Gulyás B; Hall H
Eur J Neurosci; 2005 Jul; 22(1):65-71. PubMed ID: 16029196
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D3 receptor agonists partially reproduce the discriminative stimulus effects of cocaine in squirrel monkeys.
Spealman RD
J Pharmacol Exp Ther; 1996 Sep; 278(3):1128-37. PubMed ID: 8819495
[TBL] [Abstract][Full Text] [Related]
12. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of novel properties of the human D3 dopamine receptor.
Kuzhikandathil EV; Westrich L; Bakhos S; Pasuit J
Mol Cell Neurosci; 2004 May; 26(1):144-55. PubMed ID: 15121186
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines.
Tang L; Todd RD; Heller A; O'Malley KL
J Pharmacol Exp Ther; 1994 Jan; 268(1):495-502. PubMed ID: 8301592
[TBL] [Abstract][Full Text] [Related]
15. Autoradiographic localization of [3H]quinpirole binding to dopamine D2 and D3 receptors in rat brain.
Gehlert DR; Gackenheimer SL; Seeman P; Schaus J
Eur J Pharmacol; 1992 Feb; 211(2):189-94. PubMed ID: 1351846
[TBL] [Abstract][Full Text] [Related]
16. Characterization of [3H]quinpirole binding to human dopamine D2A and D3 receptors: effects of ions and guanine nucleotides.
Malmberg A; Mohell N
J Pharmacol Exp Ther; 1995 Aug; 274(2):790-7. PubMed ID: 7636742
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
18. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
[TBL] [Abstract][Full Text] [Related]
19. Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine2 and 5-hydroxytryptamine1c serotonin receptors.
Choudhary MS; Craigo S; Roth BL
Mol Pharmacol; 1992 Oct; 42(4):627-33. PubMed ID: 1435740
[TBL] [Abstract][Full Text] [Related]
20. Lack of functional D2 receptors prevents the effects of the D3-preferring agonist (+)-PD 128907 on dialysate dopamine levels.
Zapata A; Shippenberg TS
Neuropharmacology; 2005 Jan; 48(1):43-50. PubMed ID: 15617726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
